(Q30317994)
Statements
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III) (English)
Hans-Joachim Schmoll
Alberto Sobrero
Philippe Rougier
Sheryl L Koski
Ilona Kocakova
Paul Mainwaring
Ramon Salazar
Peter Barker
Bijoyesh Mookerjee
Jane Robertson
Eric Van Cutsem
10 September 2012